Alternate Name(s):
RIFADIN®
Classification:
Antibiotic
Original Date:
August 2005
Revised Date:
June 2014
Indications:
- Treatment of tuberculosis
- For synergy to treat resistant bacterial infections
Reconstitution and Stability:
|
VIAL SIZE |
STERILE WATER for INJECTION REQUIRED |
FINAL CONCENTRATION |
|
300 mg |
5 mL |
60 mg/mL |
|
600 mg |
10 mL |
60 mg/mL |
- Protect from light
- Reconstituted solution stable 24 hours at room temperature
- Once diluted to 6 mg/mL - only stable 4 hours. Administer as soon as possible after preparation.
Compatibility:
- Solutions Compatible: D5W, NS
- Additive/Above Cassette Compatible: no information
- Y-site Compatible: no information
- Incompatible: sodium bicarbonate, diltiazem
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | NO |
| IV Direct |
NO |
| IV Intermittent Infusion | YES Usual dilution: 6 mg/mL Infusion time: 0.5-3 hours |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric:
- Tuberculosis:
- 10-20 mg/kg/day IV once daily
- Maximum: 600 mg/day
- Synergy, bacterial infections:
- 20 mg/kg/day divided every 12 hours
- Maximum: 300 mg IV Q12H
- MRSA (methicillin resistant Staphylococcus aureus) infections
Endocarditis, prosthetic valve due to MRSA:
- Infants and Children: 15 - 20 mg/kg/day divided Q8H
- Maximum: 300 mg IV Q8H
- Therapeutic note: Treat for at least 6 weeks (combine with vancomycin for the entire duration of therapy and gentamicin for the first 2 weeks)
Adult:
- Tuberculosis:
- 10 mg/kg/day IV once daily
- Maximum: 600 mg/day
Potential hazards of parenteral administration:
- Headache, confusion, fever, ataxia
- Nausea, vomiting, diarrhea
- Hypersensitivity, pruritus, skin rash
- Hepatitis, elevated liver enzymes
- Elevations of serum urea and uric acid
- Leukopenia, thrombocytopenia, hemolytic anemia
- Thrombophlebitis, irritation, pain and swelling at injection site with prolonged use (>30 days)
Notes:
- May discolour body fluids to red-orange colour
- Monitor periodic liver function tests, CBC, bilirubin, platelet count
- May decrease serum concentration of many medications (eg. anticoagulants). Consult Pharmacy
- Avoid extravasation during injection: local irritation and inflammation due to extravascular infiltration of the infusion may occur. If so, discontinue and start at another site